摘要
目的:探讨放化疗联合DC-CIK治疗脑胶质瘤复发的临床疗效和安全性。方法:选择我院自2006年1月至2011年9月收治的40例脑胶质瘤复发患者,采用放化疗联合DC-CIK治疗。统计记录治疗效果、生存期、治疗并发症和生活质量评分。结果:40例患者完全缓解8例,部分缓解11例,稳定10例,恶化11例,总治疗有效率为47.5%,在消化道反应、血象异常、内分泌紊乱、感染发热、呼吸道炎症等项目上并发症的发生率均维持在低水平,3、9、15个月生存率分别为85.7%、65.7%、40.0%,KPS评分为78.5±8.6,组间差异有统计学意义(P<0.05)。结论:放疗联合DC-CIK能提高脑胶质瘤复发患者的生活质量,延长生存期。
Objective： To observe recurrent glioma clinical efficacy of chemotherapy combined DC-CIK treatment in 40 cases. Methods： Screening patients admitted to our hospital from January 2006 to September 2011, 40 cases of recurrent glioma patients were treated by chemotherapy combined DC-CIK treatment. The therapeutic effect of the statistical records, survival, treatment complications, and quality of life score were calculated and analyzed. Results： For 40 patients with complete remission in 8 cases, partial remission in 11 cases, 10 cases of stable, deterioration of the 11 cases, the total effective rate 47.5%, gastrointestinal reactions, blood abnormalities, endocrine disorders, infection, fever, respiratory inflammation and other projects complications occurred and had been maintained at a low level, 3,9,15 month survival rates were 85.7%, 65.7%, 40.0%, KPS score was 78.54 8.6, the difference between the groups was statistically significant （P 〈0.05）. Conclusion： Radiotherapy combined DC-CIK can improve the quality of life in patients with glioma recurrence and prolong survival.
出处
《现代生物医学进展》
CAS
2013年第20期3860-3862,3919,共4页
Progress in Modern Biomedicine
基金
广西卫生厅基金项目:脑胶质细胞瘤术后间质内照射治疗(Z2005174)
关键词
脑胶质瘤
放化疗
细胞过继免疫治疗
Glioma
Chemoradiotherapy
Cells in adoptive immunotherapy
